BURLINGTON, Mass., Dec. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for craniomaxillofacial (CMF) devices in the United States and Europe will grow through 2023. The market will be bolstered by a variety of factors, including the growth of older population segments, as well as an increase in vehicle miles traveled. Both of these factors increase the incidence of traumatic injuries, including head injuries, which can be treated using craniomaxillofacial devices.

Other key findings from Decision Resources Group's coverage of the U.S. and European CMF device markets:

  • Pricing pressures in Europe: Although pricing pressure will exist in both markets, it will be more severe in Europe. An increase in regional tenders and the growing presence of group purchasing organizations will contribute to pricing declines in the region.
  • Adoption of premium-priced products in the U.S.: By contrast, prices in many CMF device markets in the U.S. will increase as a result of the ongoing adoption of premium-priced devices. These include a wide variety of resorbable product designs, as well as DePuy Synthes' recently launched Patient Specific Plate for Mandible.
  • Lower adoption of CMF devices in Europe: In addition to strong budget constraints, awareness and acceptance of CMF devices is lower in Europe in general, and therefore manufacturers will need to invest in marketing and education initiatives in order to boost adoption.

Comments from Decision Resources Group Analyst Valentina Lim:

  • "Johnson & Johnson's acquisition of Synthes has considerably boosted the company's presence in the CMF device market, and the competitive landscape will continue to change with Zimmer's pending acquisition of Biomet and its recent acquisition of ETEX. It's likely that we'll see more merger and acquisition activity going forward as facilities increasingly purchase orthopedic devices, including CMF devices, in bulk, creating demand for large product portfolios."
  • "The CMF distraction device market has recently been limited by a class I recall of DePuy Synthes' Craniomaxillofacial Mandibular Distraction system. Since the recall, concerns of serious complications associated with the company's distractor devices have received media attention, and lawsuits have been filed against DePuy Synthes. Although this recall happened in the U.S., it has reduced confidence in distraction devices in general worldwide."

Additional Resources:

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Tori McClain

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

PCSK9 and CETP Inhibitors Are Set to Transform the Dyslipidemia Market

View Now